Horke Alexander, Tudorache Igor, Laufer Günther, Andreas Martin, Pomar Jose L, Pereda Daniel, Quintana Eduard, Sitges Marta, Meyns Bart, Rega Filip, Hazekamp Mark, Hübler Michael, Schmiady Martin, Pepper John, Rosendahl U, Lichtenberg Artur, Akhyari Payam, Jashari Ramadan, Boethig Dietmar, Bobylev Dmitry, Avsar Murat, Cebotari Serghei, Haverich Axel, Sarikouch Samir
Department for Cardiothoracic, Transplant, and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria.
Eur J Cardiothorac Surg. 2020 Nov 1;58(5):1045-1053. doi: 10.1093/ejcts/ezaa100.
Decellularized aortic homografts (DAH) may provide an additional aortic valve replacement option for young patients due to their potential to overcome the high early failure rate of conventional allogenic and xenogenic aortic valve prostheses.
A prospective, European Union-funded, single-arm, multicentre, safety study was conducted in 8 centres evaluating non-cryopreserved DAH for aortic valve replacement.
One hundred and forty-four patients (99 male) were prospectively enrolled between October 2015 and October 2018, mean age 33.6 ± 20.8 years; 45% had undergone previous cardiac operations. Mean implanted DAH diameter 22.6 ± 2.4 mm and mean durations for the operation, cardiopulmonary bypass and cross-clamp were 341 ± 140, 174 ± 80 and 126 ± 43 min, respectively. There were 2 early deaths (1 LCA thrombus on day 3 and 1 ventricular arrhythmia 5 h postop) and 1 late death due to endocarditis 4 months postoperatively, resulting in a total mortality of 2.08%. One pacemaker implantation was necessary and 1 DAH was successfully repaired after 6 weeks for early regurgitation following subcoronary implantation. All other DAH were implanted as a free-standing root. After a mean follow-up of 1.54 ± 0.81 years, the primary efficacy end points peak gradient (mean 11.8 ± 7.5 mmHg) and regurgitation (mean 0.42 ± 0.49, grade 0-3) were excellent. At 2.5 years, freedom from explantation/endocarditis/bleeding/stroke was 98.4 ± 1.1%/99.4 ± 0.6%/99.1 ± 0.9%/99.2 ± 0.8%, respectively, with results almost identical to those in an age-matched Ross operation cohort of 212 patients (mean age 34 years) despite DAH patients having undergone >2× more previous procedures.
The initial results of the prospective multicentre ARISE trial show DAH to be safe for aortic valve replacement with excellent haemodynamics in the short follow-up period.
去细胞化主动脉同种异体移植物(DAH)可能为年轻患者提供另一种主动脉瓣置换选择,因为其有可能克服传统同种异体和异种主动脉瓣假体早期高失败率的问题。
在8个中心开展了一项前瞻性、由欧盟资助的单臂、多中心安全性研究,评估用于主动脉瓣置换的非冷冻保存DAH。
2015年10月至2018年10月前瞻性纳入了144例患者(99例男性),平均年龄33.6±20.8岁;45%的患者曾接受过心脏手术。植入的DAH平均直径为22.6±2.4mm,手术、体外循环和阻断主动脉的平均持续时间分别为341±140、174±80和126±43分钟。有2例早期死亡(1例术后3天发生左冠状动脉血栓,1例术后5小时发生室性心律失常),1例术后4个月因心内膜炎晚期死亡,总死亡率为2.08%。有1例需要植入起搏器,1例DAH在冠状动脉下植入后6周因早期反流成功修复。所有其他DAH均作为独立根部植入。平均随访1.54±0.81年后,主要疗效终点峰值梯度(平均11.8±7.5mmHg)和反流(平均0.42±0.49,0 - 3级)情况良好。在2.5年时,免于植入物取出/心内膜炎/出血/中风的比例分别为98.4±1.1%/99.4±0.6%/99.1±0.9%/99.2±0.8%,尽管接受DAH治疗的患者既往手术次数是年龄匹配的212例Ross手术队列患者(平均年龄34岁)的两倍多,但结果几乎相同。
前瞻性多中心ARISE试验的初步结果表明,DAH用于主动脉瓣置换在短期随访期内是安全的,血流动力学良好。